- Home
- GH vs RPRX Comparison
GH vs RPRX Comparison
Compare GH & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GH | RPRX |
|---|---|---|
| Founded | 2011 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9B | 25.9B |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GH | RPRX |
|---|---|---|
| Price | $158.26 | $61.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 26 | 8 |
| Target Price | ★ $201.64 | $65.38 |
| AVG Volume (30 Days) | 1.8M | ★ 2.6M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 1.58% |
| EPS Growth | ★ 6.74 | N/A |
| EPS | N/A | ★ 0.71 |
| Revenue | $982,021,000.00 | ★ $2,378,193,000.00 |
| Revenue This Year | $38.42 | $47.38 |
| Revenue Next Year | $35.13 | $8.97 |
| P/E Ratio | ★ N/A | $83.96 |
| Revenue Growth | ★ 32.88 | 5.06 |
| 52 Week Low | $65.96 | $35.92 |
| 52 Week High | $191.05 | $64.38 |
Technical Indicators
Market Signals| Indicator | GH | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.93 | 62.85 |
| Support Level | $153.88 | $55.04 |
| Resistance Level | $173.94 | $64.38 |
| Average True Range (ATR) | 8.16 | 1.19 |
| MACD | -2.16 | 0.42 |
| Stochastic Oscillator | 1.83 | 94.41 |
Price Performance
Historical ComparisonAbout GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.